icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
In Vitro Resistance Analysis of Merck's HCV NS5a Inhibitor MK-8742 Demonstrates Increased Potency AgainstClinical Resistance Variants and Improved Resistance Profile
 
 
  Reported by Jules Levin
EASL 2012 April 18-22 Barcelona Spain
 
Rong Liu*, Rong (Stephanie) Kong, Paul Mann, Paul Ingravallo, Ying Zhai, Ellen Xia, Peter Meinke, David Olsen, Steve Ludmerer, Joseph Kozlowski, Craig Coburn. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif